Tailored therapy for chronic myeloid leukaemia
Published 5 December 2019 Rebecca Warvinge receives award for CML research. Photo: Åsa Hansdotter Chronic myeloid leukaemia (CML) is a slowly progressing form of blood cancer that attacks the blood-forming cells in the bone marrow. The condition requires lifelong treatment that can cause severe side effects. Rebecca Warfvinge maps stem cells in patients in the hope of identifying predictive marker
https://www.stemcellcenter.lu.se/article/tailored-therapy-chronic-myeloid-leukaemia - 2025-03-16